In HCC, ICIs targeting programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have demonstrated promising clinical activity. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.